JOHN KASTELEIN, Academic Medical Center, Amsterdam REFERENCE: Abstract 407-7, American College of Cardiolgy New Orleans A drug which raises HDL and reduces circulating levels of LDL has nevertheless f
JOHN KASTELEIN, Academic Medical Center, Amsterdam
REFERENCE: Abstract 407-7, American College of Cardiolgy New OrleansA drug which raises HDL and reduces circulating levels of LDL has nevertheless failed to reduce atherosclerotic progression in patients with familial hypercholesterolemia. This disappointing outcome of a study using the cholesteryl ester transfer protein inhibitor (CETP), torcetrapib, was announced at the American College of Cardiology meeting in New Orleans.John Kasteleindiscussed the findings, and their implications for therapies targeting HDL, with Peter Goodwin.
Related Episodes
Bivalirudin For Angioplasty: Expensive Heparin?
Tony Gershlick Tony Gershlick, University of Leicester Adnan Kastrati, Deutsches Herzzentrum, Munich Using bivalirudin instead of heparin during angioplasty wasn’t any better for preventing deat
Remove Thrombus Before Primary Angioplasty!
Felix Zijlstra Felix Zijlstra, University Medical Center Groningen, The Netherlands Thrombus aspiration before percutaneous coronary intervention for acute myocardial infarction has multiple benefits,
Never Too Old For Hypertension Treatment!
Nigel Beckett Nick Boon Nigel Beckett, Imperial College, London COMMENT: Nick Boon, British Cardiovascular Society, London Even very old patients benefit greatly if you treat their hypertension. This